C-Reactive Protein as a Prognostic Indicator in COVID-19 Patients

Sadeghi–Haddad–Zavareh, Mahmoud; Bayani, Masomeh; Shokri, Mehran; Ebrahimpour, Soheil; Babazadeh, Arefeh; Mehraeen, Rahele; Moudi, Emadoddin; Rostami, Ali; Barary, Mohammad; Hosseini, Akram Sadat; Bijani, Ali; Javanian, Mostafa

doi:10.1155/2021/5557582

Cited by 62 publications

(58 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) has resulted in many individuals becoming infected, more than four million deaths, and has placed an unprecedented burden on public health services worldwide. 1 , 2 , 3 Vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials.…”

Section: Introductionmentioning

confidence: 99%

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Afshar

Babazadeh

Janbakhsh

et al. 2021

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

Summary Vaccination against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) is a crucial step in ending the current worldwide pandemic. However, several particularly vulnerable groups in the population were not included in sufficient numbers in coronavirus disease 2019 (Covid‐19) vaccine trials. Therefore, as science advances, the advice for vaccinating these special populations against Covid‐19 will continue to evolve. This focused review provides the latest recommendations and considerations for these special populations (i.e., patients with rheumatologic and autoimmune disorders, cancer, transplant recipients, chronic liver diseases, end‐stage renal disease, neurologic disorders, psychiatric disorders, diabetes mellitus, obesity, cardiovascular diseases, chronic obstructive pulmonary disease, human immunodeficiency virus, current smokers, pregnant and breastfeeding women, the elderly, children, and patients with allergic reactions) using the currently available research evidence.

show abstract

Section: Introductionmentioning

confidence: 99%

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Afshar

Babazadeh

Janbakhsh

et al. 2021

Reviews in Medical Virology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Patients with CRP > 64.75 mg/L on admission were more likely to have severe complications of COVID-19 [16]. Stringer et al reported that a CRP cutoff of ≥40 mg/L on admission was a good indicator of mortality in patients with COVID-19 [17].…”

Section: Discussionmentioning

confidence: 99%

“…CRP ≥ 110 mg/L is associated with moderate-to-severe acute respiratory distress syndrome in patients with COVID-19 (Poggiali et al, 2020). Patients with CRP > 64.75 mg/L on admission were more likely to have severe complications of COVID-19 (Sadeghi-Haddad-Zavareh et al,2021). Stringer et al reported that a CRP cutoff of ≥40 mg/L on admission was a good indicator of mortality in patients with COVID-19 (Stringer et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

C-reactive protein and lactate dehydrogenase as prognostic indicators in COVID-2019 outpatients

Suzuki

2021

Preprint

View full text Add to dashboard Cite

BackgroundIt is critical for clinicians seeing outpatients with coronavirus disease 2019 (COVID-19) to identify those who will require oxygen therapy after the hospital visit. Although many studies on biomarkers predicting the study outcomes, including intensive care unit admission, ventilator requirement, or mortality, in hospitalized patients with COVID-19 have been conducted, research on biomarkers predicting the need for oxygen therapy in outpatients is sparse.MethodsPatients with COVID-19 who visited Asahikawa City Hospital on an outpatient basis were included in the study. In total, 287 new outpatients visited between April 2021 and September 2021, and 142 underwent blood testing. All blood tests were performed before any treatments for COVID-19 were started. Demographic information, laboratory data, and clinical treatment information were extracted from the electronic medical records. Risk factors associated with oxygen therapy were explored.ResultsIn total, 40 of 142 patients who underwent blood testing required oxygen therapy within 7 days after blood samples were taken, and all other patients recovered without oxygen therapy. C-reactive protein (CRP) and lactate dehydrogenase (LDH) levels were significantly higher in patients who required oxygen therapy, and their cutoffs were 36 mg/L (sensitivity, 0.802; specificity, 0.725) and 267 U/L (sensitivity, 0.713; specificity, 0.750), respectively. Multivariate logistic regression identified age, body mass index, CRP ≥ 36 mg/L, and LDH ≥ 267 U/L as significant risk factors for oxygen therapy.ConclusionThis study suggests that elevated CRP and LDH levels are useful biomarkers for predicting the need for oxygen therapy in outpatients with COVID-19. Further confirmatory studies are needed.

show abstract

“…Слід зазначити, що у пацієнтів на ЗНТ за методом ГД адекватність діалізної терапії, визначеної за рівнем сечовини та креатиніну була недостатньою (сечовина -28,2±1,5, креатинін 764,0±17,6), що призвело до більш виразної загальної запальної реакції, яка характеризувалася найвищим рівнем СРБ (64,4±5,1 мг/л) в даній групі пацієнтів. Згідно сучасних уявлень підвищення рівня СРБ є раннім біомаркером важкого перебігу коронавірусної інфекції [13,14,15]. Перебіг захворювання у пацієнтів на гемодіалізі був також ускладнений анемією: середній рівень гемоглобіну склав 82,6±3,4 г/л і був достовірно нижчим за аналогічний показник у групах пацієнтів, які знаходилися на перітонеальному діалізі та реципієнтів ниркового трансплантату Резюме.…”

Section: дана робота є ініціативним дослідженнямunclassified

Peculiarities of the Course of COVID-19 in Patients with Chronic Kidney Disease Receiving Renal Replacement Therapy

Андон'єва¹,

Kolupayev²,

Dubovik³

et al. 2021

Ukr. ž. med. bìol. sportu

View full text Add to dashboard Cite

Patients with chronic kidney disease stage 5 belong to the group of patients with the highest risk of complicated course of COVID-19. The purpose of the study was to study the prevalence and clinical and laboratory features of the COVID-19 infection among patients with end-stage of chronic kidney disease who receive renal replacement therapy. Materials and methods. The study included 172 patients with chronic kidney disease stage 5, who were receiving renal replacement therapy and who were diagnosed with COVID-19 for the period from April 2020 to April 2021. According to the type of renal replacement therapy all patients were divided into 3 groups: group 1 – 98 (56.9%) patients who received hemodialysis, group 2 – 60 (34.8%) patients who were on peritoneal dialysis, group 3 – 14 (8.1%) patients with kidney transplantation. The main clinical and laboratory parameters that characterize the course of the COVID-19 infection such as fever, diarrhea, anosmia, the percentage of oxygen saturation, the percentage of lung damage, levels of total protein, albumin, C-reactive protein, urea, creatinine, D-dimer, hemoglobin, leukocytes, platelets were evaluated. Results and discussion. The COVID-19 infection was diagnosed in 172 (38.2%) patients, the vast majority of whom – 110 (63.9%) patients were women with a mean age of 47.4±4.6 years. The analysis of clinical and laboratory parameters revealed the most severe course of the disease in patients with a kidney transplant and in patients who were on hemodialysis. In the group of renal transplant recipients there was a significant increase in the level of D-dimer, as well as a higher percentage of lung damage, compared with the average values of these indicators among patients on hemodialysis and peritoneal dialysis, but mortality in this group was 13.3% and was significantly lower than in the group of hemodialysis patients – 27.5%. It should be noted that in patients on renal replacement therapy by the method of hemodialysis, the adequacy of dialysis therapy was insufficient, which led to a more pronounced overall inflammatory response, which was characterized by the highest level of C-reactive protein (64.4±5.1 mg/l), compared with patients in the other study groups. The course of the disease in patients on hemodialysis was also complicated by anemia. In patients on renal replacement therapy by peritoneal dialysis, the COVID-19 infection was characterized by a mild course, with the lowest percentage of lung damage (22.0±2.8%) and fatalities (11.6%). Conclusion. According to our study, the incidence of COVID-19 among patients receiving renal replacement therapy is 38.2%. A more severe course of the disease was registered in the group of patients with a kidney transplant, due to the nature of comorbid pathology, as well as immunosuppressive therapy. The data obtained allow us to consider patients with a transplanted kidney as a risk group for severe COVID-19 infection

show abstract

C-Reactive Protein as a Prognostic Indicator in COVID-19 Patients

Cited by 62 publications

References 14 publications

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

Coronavirus disease 2019 (Covid‐19) vaccination recommendations in special populations and patients with existing comorbidities

C-reactive protein and lactate dehydrogenase as prognostic indicators in COVID-2019 outpatients

Peculiarities of the Course of COVID-19 in Patients with Chronic Kidney Disease Receiving Renal Replacement Therapy

Contact Info

Product

Resources

About